Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.62 |
| ▸ | MTOR | P42345 | 20/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.62 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL54371 | 0.88 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL61796 | 0.84 | PIK3CA (0.50) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL30151212 | 0.83 | PIK3CA (0.55) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL60884 | 0.83 | PIK3CA (0.47) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL60917 | 0.83 | PIK3CA (0.61) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL61392 | 0.82 | PIK3CA (0.61) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL3657124 | 0.82 | PIK3CA (0.70) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL54445 | 0.82 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| Methyl Alcohol SCHEMBL3658444 | 0.80 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3R1SMG1 | |
| SCHEMBL3656780 | 0.80 | PIK3CA (0.87) | PIK3CAMTORPIK3CDPIK3R1SMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.